Hyperprolactinemia in Systemic Lupus Erythematosus?

References

• Smith P E. The effect of hypophysectomy upon the involution of the thymus in rat. Anat Rec 1930; 47: 119–29
   Google Scholar
• Nagy E, Berczi I, Wren G E, Asa S L, Kovaks K. Immunomodulation by bromocriptine. Immunopharmacology 1983; 6: 231–43
   PubMed Web of Science ®Google Scholar
• Dineen J K, Kelly J D. The suppression of rejection of Nippostrongylus brasiliensis in lactating rats: the nature of immunologic defect. Immunology 1973; 24: 552–8
   Google Scholar
• Russel D H. New aspects of prolactin and immunity: A lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 1989; 10: 40–4
   PubMedGoogle Scholar
• Berzci I, Nagy E, Asa S, Kovacs K. The influence of pituary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682–7
   PubMedGoogle Scholar
• Riskind P N, Massacesi L, Dolittle T H, Hauser S L. The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. Ann Neurol 1991; 29: 542–7
   PubMed Web of Science ®Google Scholar
• Palestine A G, Nussenblatt R B, Gelato M. Therapy for autoimmune uveitis with low-dose cyclosporin plus bromocriptine. Transplant Proc 1988; 20: 131–5
   PubMed Web of Science ®Google Scholar
• Ferrari C, Boghen M, Paracchi A. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1983; 104: 35–41
   PubMedGoogle Scholar
• Lavalle C, Loyo E, Panigua R. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987; 14: 268–72
   PubMed Web of Science ®Google Scholar
• Folomeev M, Prokaeva T, Nassonova V, Nassonev E, Masenko E, Ovtraht N. Prolactin levels in men with SLE and RA (letter). J Rheumatol 1991; 18: 349–53
   PubMedGoogle Scholar
• Jarae-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormone during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349–53
   PubMedGoogle Scholar
• Jara L J, Gomez-Sanchez C, Silveira L H, Martinez-Osuna P, Vassey F B, Espinoza L R. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci 1992; 303: 222–6
   PubMed Web of Science ®Google Scholar
• Mc Murray R W, Allen S H, Braun A L, Rodriguez F, Walker S E. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: Possible hormonal stimulation of an autoimmune disease. J Rheumatol 1994; 21: 5, 843–50
   Google Scholar
• Mc Murray RKeisler W. D, Kanuckel K, Izui S, Walker S E. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147: 3780–7
   PubMedGoogle Scholar
• Mc Murray R W, Keisler D, Walker S E. Hyperprolactinemia accelerates disease activity in the male NZB/W mouse model of SLE. Arthritis Rheum 1991; 34: S163, abstr C 182
   Google Scholar
• Mc Murray R W, Keisler D, Tzui S, Hoffman R W, Walker S E. Postpartum disease activity in the female b/w mouse model of SLE. Arthritis Rheum 1991; 34: S163, abstr C 183
   Google Scholar
• Berzci I, Nagy E, Asa S, Kovacs K. The influence of pituary hormones on adjuvant arthritis. Arthritis Rheum 1984; 27: 682–7
   PubMedGoogle Scholar
• Neidhart M, Larson D F. Freund's complete adjuvant induces descarboxylase activity in the central nervous system of male rats and triggers the releases of pituary hormones. J Neuroimmunol 1990; 26: 97–105
   PubMed Web of Science ®Google Scholar
• Weber G, Frey H. Zur Behandlung der Psoriasis arthropatica mit Bromocriptin. Z Hautkr 1986; 61: 1456–66
   PubMedGoogle Scholar
• Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol 1991; 18: 611–2
   PubMed Web of Science ®Google Scholar
• Hedner L P, Bynke G. Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 1985; 100: 618–9
   PubMedGoogle Scholar
• Bravo G, Zazueta B, Lavalle C. An acute remission of Reiter's syndrome in male patients treated with bromocriptine. J Rheumatol 1992; 19: 747–50
   PubMedGoogle Scholar
• Walker S E, Allen S H, Hoffman R W, McMurray R W. Review - Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus 1995; 4: 3–9
   PubMed Web of Science ®Google Scholar
• Tan E M, Cohen A S, Fries J F, Masi A T, Mc Shane D J, Rothfield N F, Schaller J G, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7
   PubMed Web of Science ®Google Scholar
• Schneider M, Hengst K, Waldendorf B, Högemann B, Gerlach U. The value of serum laminin PI in monitoring disease activity in patients with systemic lupus erythematosus. Scand J Rheumatology 1988; 17: 417–22
   PubMed Web of Science ®Google Scholar
• Lavalle C. Prolactin - A hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic diseases. J Rheumatol 1992; 19: 6, 839–41
   Google Scholar
• Jara L J, Lavalle C, Espinoza L R. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus. J Rheumatol 1992; 19: 9, 1333–6
   Google Scholar
• Espinoza L R. Prolactin. Its potential role in systemic erythematosus (SLE). Lupus (abstr), abstracts from the Fourth International Conference on SLE. 1995, 66, 4 (suppl 2)
   Google Scholar
• Jara L J, Lavalle C, Fraga A, Gomez-Sanchez C, Silveira L H. Prolactin, Immunoregulation and autoimmune diseases. Semin Arthritis Rheum 1991; 20: 5, 273–84
   Google Scholar
• Reber P M. Prolactin and immunomodulation. Am J Med 1993; 95: 637–44
   PubMed Web of Science ®Google Scholar
• Pauzner R, Urowitz M B, Gladman D, Gough J M. Prolactin in systemic Lupus erythematosus. J Rheumatol 1994; 21: 11, 2064–7
   Google Scholar
• Conconi M, Walker A M. Chloroquine affects prolactin secretion and golgi morphology in the mammotroph. Endocrinology 1984; 114: 725–34
   PubMedGoogle Scholar
• Ben-David M, Danon A, Benveniste R. Results of radioimmunoassays of rat pituitary and serum prolactin after adrenalectomy and perphenazine treatment in rats. J Endocrinol 1972; 50: 559
   Google Scholar
• Stryker T D, Molitch M E. Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insuffiency. Am J Med 1985; 79: 271
   PubMed Web of Science ®Google Scholar
• Russell D H, Kiber R, Matrisian L, Larson D F, Poulos B, Magun B E. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 1985; 134: 3027–31
   PubMedGoogle Scholar
• Sakata S, Nakamura S, Milura K. Autoantibodies against thyroid hormones or iodothyronine: implications in diagnosis, thyroid function, treatment and pathogenesis. Ann Intern Med 1985; 103: 579–89
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikekubo K, Ishihara T, Mridera K, Hino M, Kurahachi H. Effects of anti-prolactin autoantibodies on serum prolactin measurements. European Journal of Endocrinology 1994; 130: 434–7
   PubMed Web of Science ®Google Scholar
• Lindstedt G. Endogenous antibodies against prolactin -“new” cause of hyperprolactinemia. European Journal of Endocrinology 1994; 130: 429–32
   PubMedGoogle Scholar
• Gala R R, Shevach E M. Identification by analytical flow cytometry of prolactin receptors on immunocompetent cell populations in the mouse. Endocrinology, 133: 1617–23
   PubMedGoogle Scholar
• Ferrai C, Boghen M, Paracchi A. Thyroid autoimmunity in hyperprolactinemic disorders. Acta Endocrinol 1982; 100: 184–8
   PubMedGoogle Scholar
• Ishibashi M, Yamaji T. Immunological abnormalities with hyperprolactinemia. The Endocrine Society, 71. Annual meeting. 1989, 407, abstr
   Google Scholar
• Honbo K S, Herle A JV, Kellett K A. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978; 64: 782
   PubMed Web of Science ®Google Scholar
• Hou S H, Grossman S, Molitch M E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985; 6: 245
   PubMedGoogle Scholar
• Lim V S, Kathpalia S C, Frohman L A. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: Reversal after transplantation. J Clin Endocrinol Metab 1979; 48: 101
   PubMed Web of Science ®Google Scholar
• Batrinos M L, Panitsa-Faflia C, Tsiganou E, Liapi C. Incidence and characteristics of microprolactinomas (3–5mm) in 4199 women assayed for prolactin. Horm Metab Res 1992; 24: 384–91
   PubMedGoogle Scholar
• Bombardier C, Gladman D D, Urowitz M B, Caron D, Chang C H. and the committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630–40
   PubMed Web of Science ®Google Scholar
• Mc Murray R W, Allen S H, Weidensaul D, Walker S E. An open label therapeutic trial of bromocriptine in systemic lupus erythematosus. Lupus 1995; 4(Suppl 2)66
   Google Scholar